psalexa
SearchBar Icon

Chronic Pain Treatment Market to Reach $105.9 Billion by 2024

Published Date:   December 2018

Chronic pain treatment market is expected to reach $105.9 billion by 2024, according to P&S Intelligence.

The market growth is primarily driven by the rising prevalence of chronic conditions, surging geriatric population, and increasing government support toward chronic pain management.

Insights into the market segments

Based on product, the chronic pain treatment market is bifurcated into drugs and devices. The category of drugs is further classified into opioids, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants, and other drugs. Opioids dominate the chronic pain drugs market, with an estimated contribution of 36.5% revenue in 2018. Opioids are considered one of the most effective drug classes for the treatment of chronic pain.

On basis of indication, the chronic pain treatment market is categorized into neuropathic pain, arthritis pain, cancer pain, chronic back pain, migraine, fibromyalgia, and others. According to the American Academy of Pain Medicine (AAPM), chronic pain affects approximately 1.5 billion people worldwide, on account of the high prevalence of cardiovascular disorders, cancer, and diabetes. During the forecast period, the market is expected to witness the fastest growth in demand for pain treatment products for cancer pain, followed by migraine.

Chronic Pain Treatment Market

Chronic pain treatment products are used in several application areas, including musculoskeletal, neuropathy, and oncology. Musculoskeletal indications constitute the largest application area of these products and are estimated to generate revenue of $31.8 billion in the chronic pain treatment market in 2018. This can be mainly attributed to the high prevalence of musculoskeletal disorders, such as osteoarthritis, back pain, and rheumatoid arthritis, across the globe.

On the basis of distribution channel, the chronic pain treatment market is divided into direct and indirect modes, of which the direct mode of distribution led the market in 2017 with 60.1% revenue contribution. The growing emphasis of drug and device manufacturers on direct sales is driving the market growth in this category.

Hospitals; clinics; nursing homes; and research centers and universities are the major end users in the chronic pain treatment market. Hospitals are the largest end users of chronic pain treatment products and are estimated to hold 39.7% market share in 2018. Pain treatment practices are more frequently performed in hospitals, particularly for post-surgical pain. Thus, with the growing number of surgical procedures around the world, hospitals are expected to continue generating a high demand for chronic pain treatment products.

Browse report overview with 517 tables and 70 figures spread through 423 pages and detailed TOC on "Chronic Pain Treatment Market by Product (Drugs, Devices), by Indication (Neuropathic Pain, Arthritis Pain, Chronic Back Pain, Cancer Pain, Migraine, Fibromyalgia), by Application (Musculoskeletal, Neuropathy, Oncology), by Distribution Channel (Direct, Indirect), by End User (Hospitals, Clinics, Nursing Homes, Research Centers & Universities), by Geography (U.S., Canada, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Sweden, Switzerland, Japan, China, India, Australia, South Korea, Brazil, Mexico, Saudi Arabia, South Africa) – Global Market Size, Share, Development, Growth, and Demand Forecast, 2014–2024" at:https://www.psmarketresearch.com/market-analysis/chronic-pain-treatment-market

Market is to witness the fastest growth in Asia-Pacific (APAC)

During the forecast period, the chronic pain treatment market is expected to witness the fastest growth in the APAC region. This can be mainly attributed to the high prevalence of chronic pain among people in the region. Among all age groups, the elderly are the most susceptible to chronic conditions, such as arthritis, neuropathic disorders, and back pain. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the number of aged people in the region is expected to increase twofold, from 535 million in 2015 to 1.3 billion by 2050.

To reduce the prevalence of chronic pain in the region, several government organizations are providing advanced healthcare services that help people manage pain-related conditions. For instance, Painaustralia, one of the key Australian pain advocacy bodies working toward improving the quality of life of patients living with pain, launched a national pain strategy in 2011, to provide evidence-based pain management services that focus on interdisciplinary care at all levels of the health system. Through this strategy, several initiatives have been taken to decrease the prevalence of chronic pain in Australia.

Increasing product approvals continue to support the market growth

Increasing product approvals are paving the way for various market players to expand their product portfolio in the chronic pain treatment industry. For instance, in November 2018, Pfizer Inc. announced that it was granted pediatric exclusivity for LYRICA by the United States Food and Drugs Administration (USFDA). The grant extended the period of the U.S. market exclusivity for LYRICA by an additional six months till June 2019. LYRICA is currently approved in the U.S. for fibromyalgia, diabetic nerve pain, spinal cord injury nerve pain, and pain caused by shingles in adults. It is also approved as an adjunctive therapy for the treatment of partial onset seizures in patients aged four years and above.

Furthermore, in November 2018, Abbott Laboratories launched the dorsal root ganglion (DRG) Invisible Trial System. Abbott's DRG is a form of neurostimulation therapy that specifically targets the DRG. The therapy blocks pain signals transmitted via the DRG, thereby providing relief in chronic pain. With the DRG Invisible Trial System, the patient can use an Apple iPod touch to manage pain by changing the stimulation settings within prescribed limits.

Some of the other key players operating in the global chronic pain treatment market are Eli Lilly and Company; GlaxoSmithKline plc; Medtronic plc; Boston Scientific Corporation; Novartis AG; Johnson & Johnson; AstraZeneca PLC; Bristol-Myers Squibb Company; Becton, Dickinson and Company; and Sanofi.

GLOBAL CHRONIC PAIN TREATMENT MARKET SEGMENTATION

By Product

  • Drugs
    • Opioids
    • Non-steroidal anti-inflammatory drugs (NSAIDs)
    • Anticonvulsants
    • Antidepressants
    • Others
  • Devices
    • Neurostimulation devices
      • Spinal cord stimulation (SCS) devices
      • Transcutaneous electrical nerve stimulation (TENS) devices
      • Others
    • Analgesic infusion pumps
    • Ablation devices
      • Radiofrequency ablation devices
      • Cryoablation devices
    • Others

By Indication

  • Neuropathic Pain
  • Arthritis Pain
  • Chronic Back Pain
  • Cancer Pain
  • Migraine
  • Fibromyalgia
  • Others

By Application

  • Musculoskeletal
  • Neuropathy
  • Oncology
  • Others

By Distribution Channel

  • Direct
  • Indirect

By End User

  • Hospitals
  • Clinics
  • Nursing Homes
  • Research Centers and Universities
  • Others

By Geography

  • North America Chronic Pain Treatment Market
    • By product
    • By indication
    • By application
    • By distribution channel
    • By end user
    • By country
      • U.S. chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
      • Canada chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
  • Europe Chronic Pain Treatment Market
    • By product
    • By indication
    • By application
    • By distribution channel
    • By end user
    • By country
      • Germany chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
      • France chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
      • U.K. chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
      • Italy chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
      • Spain chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
      • Netherlands chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
      • Russia chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
      • Sweden chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
      • Switzerland chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
  • Asia-Pacific (APAC) Chronic Pain Treatment Market
    • By product
    • By indication
    • By application
    • By distribution channel
    • By end user
    • By country
      • Japan chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
      • China chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
      • India chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
      • Australia chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
      • South Korea chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
  • Latin America (LATAM) Chronic Pain Treatment Market
    • By product
    • By indication
    • By application
    • By distribution channel
    • By end user
    • By country
      • Brazil chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
      • Mexico chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
  • Middle East and Africa (MEA) Chronic Pain Treatment Market
    • By product
    • By indication
    • By application
    • By distribution channel
    • By end user
    • By country
      • Saudi Arabia chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user
      • South Africa chronic pain treatment market
        • By product
        • By indication
        • By application
        • By distribution channel
        • By end user